The 2026 Plan Sponsor’s Guide to PBM Contract Loopholes
Published By
Pharmalytic Advisors, LLC
Target Audience
CFOs, HR Directors, & Plan Sponsors
Abstract
Executive Summary
Under the Consolidated Appropriations Act (CAA) of 2021, employee benefit plan sponsors face unprecedented personal liability for the financial oversight of their pharmacy programs. Yet, traditional Pharmacy Benefit Manager (PBM) contracts are designed with systematic informational asymmetry.
This guide dissects the five most common contractual "blind spots" that allow PBMs to extract opaque margins from self-insured plan assets—and outlines the precise strategies required to reclaim contract integrity.
Loophole I
1. The Brand vs. Generic Reclassification Trap
One of the most lucrative margins for traditional PBMs is the unilateral right to define what constitutes a "brand" drug versus a "generic" drug.
The Loophole
Contracts often allow the PBM to classify multi-source generic drugs as "brands" when calculating plan discounts and rebate guarantees.
The Impact
By reclassifying a low-cost generic drug as a brand, the PBM can artificially meet its discount guarantees in other areas while retaining a significant spread margin. The plan sponsor pays a brand-level price for a generic drug, violating true pass-through transparency.
Strategic Fix
Require contracts to define brand and generic drugs strictly by National Drug Code (NDC) definitions from objective, third-party databases (such as Medi-Span or First Databank) with zero PBM reclassification rights.
Loophole II
2. Opaque Manufacturer Administrative Fees
When traditional contracts promise "100% rebate pass-through," PBMs frequently circumvent this language by renaming the cash flows they receive from pharmaceutical manufacturers.
The Loophole
PBMs classify a substantial portion of manufacturer payments as "administrative fees," "formulary placement fees," or "inflation protection payments" rather than "rebates."
The Impact
Since the contract only guarantees the pass-through of "rebates," the PBM legally retains up to 30% to 50% of the total manufacturer revenue generated by your plan’s utilization.
Strategic Fix
Standardize the contractual definition of manufacturer revenue to encompass all financial payments of any kind, including administrative fees, base rebates, supplemental rebates, and data fees.
Loophole III
3. Specialty Pharmacy Sourcing Spreads
Specialty medications represent less than 2% of plan utilization but frequently exceed 50% of total plan spend. This concentration makes specialty sourcing prime ground for hidden margins.
The Loophole
PBMs dictate that specialty medications must be sourced exclusively from their own vertically integrated specialty mail-order pharmacies.
The Impact
The PBM buys a specialty drug at an extremely steep manufacturer discount and bills the plan sponsor at a significantly inflated rate, pocketing an opaque "dispensing spread" that can reach thousands of dollars per therapy.
Strategic Fix
Negotiate "lesser-of" contract pricing rules, remove mandatory mail-order exclusivity, and establish auditing pathways that compare billed costs directly against Actual Acquisition Cost (AAC).
Loophole IV
4. Restricted Auditing Provisions ("The Audit Lock")
Many plan sponsors believe they have the contractual right to audit their PBM. In practice, the PBM limits the scope of these audits so severely that meaningful oversight is impossible.
The Loophole
Standard boilerplates restrict audits to once per year, limit the auditor to specific "approved" national firms (excluding contingency auditors), and restrict the review to a small sample size (e.g., a maximum of 100 random claims).
The Impact
Systematic billing errors, spread pricing violations, and rebate leakage remain completely undetected in the unaudited 98% of your plan's claims.
Strategic Fix
Ensure unrestricted claims-level audit rights. Plan sponsors must maintain the contract authority to utilize any independent auditor of their choice to review 100% of claims-level data continuously.
Loophole V
5. Mid-Year Formulary Manipulations
Rebate optimization frequently drives PBM formulary decisions, sometimes at the direct expense of the plan sponsor's financial health and clinical stability.
The Loophole
Traditional contracts grant PBMs sole discretion to alter the formulary mid-year under the guise of clinical management.
The Impact
A PBM may exclude a lower-cost generic or biosimilar in favor of an expensive brand-name drug because the brand-name manufacturer pays the PBM a higher rebate. This shifts higher net-costs and clinical disruption directly onto the plan sponsor and its members.
Strategic Fix
Demand a contract clause requiring PBM formulary changes to be approved in advance by the plan sponsor's clinical committee, backed by a financial impact analysis demonstrating a lower net-net cost for the plan.